Nkarta reports no cytokine release syndrome in 40-patient NKX019 autoimmune trial program
NKTX•Nkarta reported initial safety results from 40 patients across five autoimmune diseases in its ongoing Phase 1/2 Ntrust trials, including no cytokine release syndrome, deaths or treatment discontinuations due to adverse events.
1. Initial safety results
Nkarta presented initial NKX019 safety results from 40 patients across five autoimmune diseases at ACR Convergence 2026 on Nov. 11. The ongoing trials reported no deaths, treatment discontinuations due to adverse events or specified immune-related toxicities; severe adverse events primarily affected blood cells and were typically linked to preparatory chemotherapy, while infusion reactions resolved with supportive care.
